Biotec Services International completes its rebrand into PCI
9th February 2015, Bridgend, UK. PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has today rebranded as part of the PCI group.
This rebrand brings together the expertise of two world class organizations and significantly expands PCI’s capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products.
The broad range of services includes manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services for optimal clinical package design, global logistics planning and depot management over a wide range of temperatures from controlled ambient to -196°C, a service for which Biotec is known across the globe.
Dr Fiona Withey, Managing Director, UK Clinical Services, stated, “The rebranding of Biotec demonstrates to the global pharmaceutical community that by joining the PCI group we are able to offer a significantly increased global capacity to deliver a worldwide offering to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility. We are very excited about the investments PCI has undertaken of late, the acquisition of Biotec and Penn Pharma along with the construction of a new North American Storage, Distribution and Returns Management site, increases the breadth of the PCI service offering and provides our clients significant opportunity to engage with a truly global pharmaceutical services organization.”
Biotec recently announced the completion of an expansion to its Bridgend facilities. This development significantly expands the footprint of its clinical trial packaging and distribution services, as well as its Cold Chain expertise solutions - supporting medicines from +25°C down to -196°C. The enhanced Bridgend facilities are an important part of PCI’s network of sites encompassing both Europe and North America, providing clinical and commercial medicines to over 100 countries globally.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
